Fenofibrate, a peroxisome proliferator-activated receptor-α agonist, exerts anticonvulsive properties

Epilepsia

Volumn 50, Issue 4, 2009, Pages 943-948

  Porta, Natacha ^b,c   Vallée, Louis ^b,c   Lecointe, Cécile ^b,c   Bouchaert, Emmanuel ^d   Staels, Bart ^d   Bordet, Régis ^d   Auvin, Stéphane ^a,b,c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Antiepileptic drug; Fenofibrate; Ketogenic diet; Pentylenetetrazol; PPAR; Status epilepticus

Indexed keywords

3 HYDROXYBUTYRIC ACID; FENOFIBRATE; LITHIUM; PENTETRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PILOCARPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET THERAPY; EPILEPTIC STATE; GRAND MAL SEIZURE; KETOGENIC DIET; LIVER WEIGHT; MALE; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPIKE WAVE;

3-HYDROXYBUTYRIC ACID; ANALYSIS OF VARIANCE; ANIMALS; ANTILIPEMIC AGENTS; BODY WEIGHT; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; KETOGENIC DIET; KETONE BODIES; LITHIUM CHLORIDE; LIVER; MALE; ORGAN SIZE; PENTYLENETETRAZOLE; PILOCARPINE; PPAR ALPHA; PROCETOFEN; RATS; RATS, WISTAR; REACTION TIME;

EID: 63849178838     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01901.x     Document Type: Article

References (56)

1. Auvin S., Shin D, Mazarati A, Sankar R 2006) The utility of testing pentylenetetrazol threshold. Epilepsia 47 : 662 663.
2. Auvin S, Sankar R 2008) Inflammation, epilepsy, and anti-inflammatory therapies. In Pellock JM, Bourgeois B, Dodson W, Nordli DR Jr., Sankar R (Eds) Pediatric epilepsy: diagnosis and therapy. 3rd ed. Demos Medical Publishing, New York, pp. 751 758.
3. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E 2002) Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51 : 31 71.
4. Bishop-Bailey D 2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129 : 823 834.
5. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C 2003) Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85 : 267 273.
6. Blondeau N, Widmann C, Lazdunski M, Heurteaux C 2002) Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience 109 : 231 241.
7. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M 2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34 : 1341 1346.
8. Bough KJ, Eagles DA 1999) A ketogenic diet increases the resistance to pentylenetetrazole-induced seizures in the rat. Epilepsia 40 : 138 143.
9. Bough KJ, Gudi K, Han FT, Rathod AH, Eagles DA 2002) An anticonvulsant profile of the ketogenic diet in the rat. Epilepsy Res 50 : 313 325.
10. Buchan KW, Hassall DG 2000) PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Med Res Rev 20 : 350 366.
11. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS 2000) Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275 : 32681 32687.
12. Cullingford TE, Dolphin CT, Sato H 2002) The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain. Neuropharmacology 42 : 724 730.
13. Cullingford TE 2004) The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot Essent Fatty Acids 70 : 253 264.
14. Dahlin M, Elfving A, Ungerstedt U, Amark P 2005) The ketogenic diet influences the levels of excitatory and inhibitory amino acids in the CSF in children with refractory epilepsy. Epilepsy Res 64 : 115 125.
15. de FU, Ericsson CG, Hamsten A, Nilsson J 1995) Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Drugs Exp Clin Res 21 : 105 124.
16. de FU, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A 1996) Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 17 (Suppl. F 37 42.
17. de FU, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A 1997) Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther 11 (Suppl. 1 257 263.
18. Delerive P, De BK, Besnard S, Vanden BW, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B 1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274 : 32048 32054.
19. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R 2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23 : 6264 6271.
20. Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R 1998) Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett 98 : 13 23.
21. Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM 1998) The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 102 : 1358 1363.
22. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR 1997) Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96 : 2137 2143.
23. Fruchart JC, Duriez P, Staels B 1999) Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10 : 245 257.
24. Fruchart JC, Staels B, Duriez P 2001) PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44 : 345 352.
25. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H 1998) Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 19 (Suppl. H H42 H47.
26. Heneka MT, Landreth GE 2007) PPARs in the brain. Biochim Biophys Acta 1771 : 1031 1045.
27. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W 2001) The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J 15 : 1971 1978.
28. Kossoff EH, Laux LC, Blackford R, Morrison PF, Pyzik PL, Hamdy RM, Turner Z, Nordli DR Jr. 2008) When do seizures usually improve with the ketogenic diet? Epilepsia 49 : 329 333.
29. Lalwani ND, Reddy MK, Qureshi SA, Sirtori CR, Abiko Y, Reddy JK 1983) Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. Hum Toxicol 2 : 27 48.
30. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M 2000) Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 19 : 1784 1793.
31. Loscher W, Honack D, Fassbender CP, Nolting B 1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8 : 171 189.
32. Ma W, Berg J, Yellen G 2007) Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels. J Neurosci 27 : 3618 3625.
33. Maurois P, Rocchi S, Pages N, Bac P, Stables JP, Gressens P, Vamecq J 2008) The PPARgamma agonist FMOC-l-leucine protects both mature and immature brain. Biomed Pharmacother 62 : 259 263.
34. Moraes LA, Piqueras L, Bishop-Bailey D 2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110 : 371 385.
35. Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A 2008) The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 49 : 1230 1238.
36. Pollack GM, Shen DD 1985) A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J Pharmacol Methods 13 : 135 146.
37. Porta N, Bourgois B, Galabert C, Lecointe C, Cappy P, Bordet R, Vallée L, Auvin S (2008) Anticonvulsant effects of Linolenic acid are unrelated to brain phospholipid cell membrane compositions. Epilepsia July 24 [Epub ahead of print].
38. Rabinovitz S, Mostofsky DI, Yehuda S 2004) Anticonvulsant efficiency, behavioral performance and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3). Psychoneuroendocrinology 29 : 113 124.
39. Rogers A 1979) Nutrition. In Baker H, Lindsey J, Weisbroth S (Eds) The laboratory rat. Academic Press, Orlando, pp. 123 152.
40. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J 1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 : 410 418.
41. Sampath H, Ntambi JM 2005) Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 25 : 317 340.
42. Sander JW 1993) Some aspects of prognosis in the epilepsies: a review. Epilepsia 34 : 1007 1016.
43. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND 2007) Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. Am J Physiol Endocrinol Metab 292 : E1157 E1165.
44. Sherwin AL 1999) Neuroactive amino acids in focally epileptic human brain: a review. Neurochem Res 24 : 1387 1395.
45. Sim AK, Spencer A, Metz G, Rushton B 1981) Effect of hypolipidaemic drugs on hepatomegaly and micro-bodies in the rat. A new approach to the nature of hepatic peroxisomal proliferation. Arzneimittelforschung 31 : 1119 1126.
46. Taha AY, Huot PS, Reza-Lopez S, Prayitno NR, Kang JX, Burnham WM, Ma DW 2008) Seizure resistance in fat-1 transgenic mice endogenously synthesizing high levels of omega-3 polyunsaturated fatty acids. J Neurochem 105 : 380 388.
47. Tanaka K, Smith PF, Stromberg PC, Eydelloth RS, Herold EG, Grossman SJ, Frank JD, Hertzog PR, Soper KA, Keenan KP 1992) Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. Toxicol Appl Pharmacol 116 : 71 77.
48. Tang C, Cho HP, Nakamura MT, Clarke SD 2003) Regulation of human delta-6 desaturase gene transcription: identification of a functional direct repeat-1 element. J Lipid Res 44 : 686 695.
49. Thavendiranathan P, Chow C, Cunnane S, McIntyre BW 2003) The effect of the 'classic' ketogenic diet on animal seizure models. Brain Res 959 : 206 213.
50. Vezzani A, Granata T 2005) Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46 : 1724 1743.
51. Vining EP, Freeman JM, Ballaban-Gil K, Camfield CS, Camfield PR, Holmes GL, Shinnar S, Shuman R, Trevathan E, Wheless JW 1998) A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 55 : 1433 1437.
52. Voskuyl RA, Vreugdenhil M, Kang JX, Leaf A 1998) Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur J Pharmacol 341 : 145 152.
53. Wang ZJ, Bergqvist C, Hunter JV, Jin D, Wang DJ, Wehrli S, Zimmerman RA 2003) In vivo measurement of brain metabolites using two-dimensional double-quantum MR spectroscopy - exploration of GABA levels in a ketogenic diet. Magn Reson Med 49 : 615 619.
54. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ 2008) The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101 : 132 139.
55. Yehuda S, Carasso RL, Mostofsky DI 1994) Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol 254 : 193 198.
56. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Lazarow A, Luhovyy B, Wehrli S, Nissim I 2005) Response of brain amino acid metabolism to ketosis. Neurochem Int 47 : 119 128.